Please login to the form below
pneumonia
This page shows the latest pneumonia news and features for those working in and with pharma, biotech and healthcare.
Shionogi Europe and NHS England agree on antibiotic subscription model
England. Both drugs address vital disease areas of unmet need, in the UK and internationally, for treating serious infections including blood stream infection (BSI), sepsis and hospital- or ventilator-acquired pneumonia.
Latest news
-
NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan
Fetcroja can be used to treat urinary tract infections, including kidney infections, and Zavicefta can be used to treat patients with pneumonia and sepsis.
-
South Africa releases first real-world evidence for Omicron
pneumonia “and neither have my colleagues”.
-
Janssen’s RSV vaccine provides high protection against respiratory infections
Respiratory syncytial virus is a leading cause of bronchitis and pneumonia and one of the most common infections in the world.
-
EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
adults with pneumonia, and Eli Lilly’s rheumatoid arthritis drug Olumiant to treat hospitalised COVID-19 patients receiving oxygen.
-
AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront
The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia. ... aeruginosa) liposaccharides serotype O11, which accounts for around 22% of all P.aeruginosa hospital acquired pneumonia cases globally.
More from news
Approximately 5 fully matching, plus 128 partially matching documents found.
Latest Intelligence
-
Rethinking our approach to infectious disease preparedness
treat patients suffering from life-threatening infections, such as pneumonia or sepsis. ... These bugs can cause or worsen a patient’s pneumonia and lead to septic shock, a life- threatening complication.
-
How will COVID-19 affect uptake of vaccinations against other diseases?
Influenza is deadly – in fact, from January to mid-April this year, three times more people in the UK died from flu or pneumonia than from COVID-19.
-
How COVID-19 is accelerating the threat of antimicrobial resistance
Trisha Greenlagh, an internationally recognised primary care professor, posted on Twitter in early April pointing out the NICE guidelines about the use of antibiotics for mild COVID pneumonia.
-
As COVID-19 takes over the world, biopharma fights back
Prior research has suggested that elevated IL-6 levels are associated with a higher mortality rate in people with community-acquired pneumonia.
-
The global antibiotic crisis: a 2020 perspective
It is associated with serious illnesses such as cystic fibrosis and causes severe infections including pneumonia and urinary tract infections. ... The consequences of such severe infections include drug-resistant pneumonia and sepsis, and often prove
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Nabriva Therapeutics appoints chief medical officer
we continue to advance the legamulin programme toward a potential approval for the treatment of community-acquired bacterial pneumonia.”.
-
Nabriva Therapeutics appoints new chief commercial officer
community-acquired bacterial pneumonia.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Viral News: Covid-19 and the media, one year on
She was requesting more information about an undiagnosed pneumonia that had been found in Wuhan, China, following a tip-off from a contact in Taiwan, who had seen chatter circulating on
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Other recent progress includes NovaBiotics’ novel antimicrobial-immunomodulator, Nylexa, which is now set to enter phase 3 clinical trials in the UK for COVID-19 and non-COVID pneumonia (in hospitalised
-
July 2020: diversity and inclusion in clinical trials round-up
In light of this, Genentech have highlighted how for a study on one of their treatments for patients with severe COVID-19 pneumonia, study sites were included that are at the
-
My Dad was 'one in a million', as the saying goes. But actually he was one in 300 million (of patients worldwide with rare disease)
His medical team first thought it may have been a chest infection, then pneumonia and then Legionnaires' disease, but they soon arrived, correctly, at mesothelioma.
-
Life with multiple myeloma - why I'm a lucky man living the dream
It certainly wasn’t my first reaction when the consultant treating me for pneumonia told me I had a tumour. ... This could have been so different if I hadn’t recklessly gone skiing with what felt like flu and developed pneumonia, leading to a
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
